Tubular reabsorption and local production of urine hepcidin-25 by Peters, H.P.E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/117898
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
RESEARCH ARTICLE Open Access
Tubular reabsorption and local production of
urine hepcidin-25
Hilde PE Peters1*, Coby MM Laarakkers2, Peter Pickkers3, Rosalinde Masereeuw4, Otto C Boerman5, Annemarie Eek5,
Elisabeth AM Cornelissen6, Dorine W Swinkels2 and Jack FM Wetzels1
Abstract
Background: Hepcidin is a central regulator of iron metabolism. Serum hepcidin levels are increased in patients
with renal insufficiency, which may contribute to anemia. Urine hepcidin was found to be increased in some
patients after cardiac surgery, and these patients were less likely to develop acute kidney injury. It has been
suggested that urine hepcidin may protect by attenuating heme-mediated injury, but processes involved in urine
hepcidin excretion are unknown.
Methods: To assess the role of tubular reabsorption we compared fractional excretion (FE) of hepcidin-25 with FE
of β2-microglobulin (β2m) in 30 patients with various degrees of tubular impairment due to chronic renal disease.
To prove that hepcidin is reabsorbed by the tubules in a megalin-dependent manner, we measured urine hepcidin-
1 in wild-type and kidney specific megalin-deficient mice. Lastly, we evaluated FE of hepcidin-25 and β2m in 19
patients who underwent cardiopulmonary bypass surgery. Hepcidin was measured by a mass spectrometry assay
(MS), whereas β2m was measured by ELISA.
Results: In patients with chronic renal disease, FE of hepcidin-25 was strongly correlated with FE of β2m (r = 0.93,
P <0.01). In megalin-deficient mice, urine hepcidin-1 was 7-fold increased compared to wild-type mice (p < 0.01)
indicating that proximal tubular reabsorption occurs in a megalin- dependent manner. Following cardiac surgery,
FE of hepcidin-25 increased despite a decline in FE of β2m, potentially indicating local production at 12–24 hours.
Conclusions: Hepcidin-25 is reabsorbed by the renal tubules and increased urine hepcidin-25 levels may reflect a
reduction in tubular uptake. Uncoupling of FE of hepcidin-25 and β2m in cardiac surgery patients suggests local
production.
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Background
Hepcidin, a peptide predominantly produced by hepa-
tocytes, is a major player in iron metabolism [1,2].
Hepcidin decreases duodenal iron absorption and causes
iron sequestration in the reticulo-endothelial system
[3,4]. Hepcidin expression is induced by iron storage
and inflammation [5,6] and suppressed by hypoxia and
anemia [5]. Serum hepcidin levels are increased in pa-
tients with renal insufficiency [7,8], and this may
contribute to anemia and resistance to erythropoietin
stimulating agents.
Recent studies have pointed to the relevance of urine
hepcidin. In patients with lupus nephritis, changes in
urine hepcidin-20 and −25 predicted renal flares [9].
Even more striking were the findings of Ho et al., who
showed that patients with increased urine hepcidin levels
were at lower risk to develop acute kidney injury (AKI)
after cardiac surgery [10,11]. These results have recently
been confirmed in a larger study that included 100 pa-
tients who had undergone cardiopulmonary bypass sur-
gery (CABG) [12]. It was suggested that urine hepcidin
may protect against AKI by attenuating heme-mediated
injury.
In order to meaningfully interpret urine hepcidin as a
biomarker, knowledge of renal handling is essential.
Thus far, it is unclear which processes – filtration,
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reabsorption, local production and/or degradation- gov-
ern urine hepcidin excretion. The objective of this study
was to study the role of tubular reabsorption in kidney
hepcidin handling. Our data provide evidence for both
tubular reabsorption and local production of hepcidin in
the kidney.
Methods
Human studies
Blood and urine samples of healthy controls were col-
lected randomly throughout the day as described before
[13]. In order to assess the role of tubular reabsorption
we compared fractional excretion (FE) of hepcidin-25
with FE of β2-microglobulin (β2m) in patients with
glomerular or tubular diseases and various degrees of
impairment of tubular reabsorption. β2m is a low mo-
lecular weight protein and an established marker of
proximal tubular function. Patients were enrolled from
February 2009 to October 2010 at the Department of
Nephrology and Pediatric Nephrology, Radboud Univer-
sity Nijmegen Medical Center. Patients with biopsy
proven glomerular disease (without an interstitial
infiltrate) and patients with defined tubular diseases
(cystinosis, Dent’s disease) were enrolled. Patients with
an interstitial infiltrate as concluded from renal biopsy
investigations were excluded, since monocytes may
produce hepcidin [14].
Hepcidin-25 was also measured in patients after car-
diopulmonary bypass surgery. Patients were enrolled
consecutively from March 2008 to April 2008 at the
Department of Intensive Care Medicine, Radboud
University Nijmegen Medical Centre, and all patients
undergoing CABG were included. Serum and urine sam-
ples were obtained simultaneously either 1–2 hours after
surgery (at a time point the patient was admitted and
stable at the ICU) and 12–24 hours after the end of surgery
(morning urine collected the day after the procedure).
The study has been carried out in the Netherlands in
accordance with the applicable rules concerning the re-
view of research ethics committees and informed con-
sent. We obtained consent from healthy volunteers. The
local ethics committee waived the need to get consent
from patients as they were having blood and urine taken
as part of standard care.
Animal experiments
In order to investigate whether hepcidin is reabsorbed in
the proximal tubules in a megalin-dependent manner,
we measured urine hepcidin-1 in wild type and kidney
specific megalin-deficient C57Bl/6 mice [15]. Megalin
lox/lox; apoECre mice on a C57BL/6 background were
kindly provided by Thomas E. Willnow. The creation of
this kidney specific megalin-deficient mouse strain was
described in detail previously [15]. Animals were bred
locally and animals expressing the apoECre gene were
identified by means of polymerase chain reaction (PCR)
analysis. Animals that did not express the apoECre gene
(megalinlox/lox mice) were used as wild type controls.
Approximately 12 weeks old female mice were used.
Their diet contained 179 mg/kg iron. To collect urine
samples, mice were individually housed in metabolic
cages (TechniplastW). Mice were allowed to adapt to
these cages during 2 periods of 30 min, after which 24-
hour urine samples were collected. Prior to 24 h housing
in metabolic cages, 2×0.5 ml salt solution was
administered subcutaneously to prevent dehydration. To
prevent hypothermia, room temperature was raised to
24°C with a relative humidity of 53-68%. Food and water
were available ad libitum. Mice were sacrificed after
blood sampling at the end of the 24-hour urine collec-
tion. Urinary protein profile of wild-type and megalin
deficient mice was determined by gel electrophoresis.
Experiments were approved by the Animal Ethical
Commission of the Radboud University Nijmegen Medical
Centre and performed in accordance with national guide-
lines for the care and handling of animals.
Laboratory measurements
Urine and serum samples were processed, aliquoted, and
stored in polypropylene tubes at −80°C immediately after
collection. Routine laboratory parameters and hepcidin
levels were measured within 8 hours and 6 months of
collection, respectively.
Urinary and serum creatinine were measured with an
enzymatic method. Urine β2m was measured by ELISA.
Urine β2m was only measured in urine with a urinary
pH >6.0, since degradation of β2m may occur below this
pH. Human hepcidin-25 was measured by our previ-
ously described weak cation exchange time-of-flight
mass spectrometry assay [16] (TOF MS). Hepcidin-1 in
urine from mice was measured by surface-enhanced
laser desorption ionization (SELDI) TOF MS [17].
Calculations and statistics
Depending on its distribution, data were expressed as
median (interquartile range) or mean ± standard devi-
ation (SD). Fractional excretion of substance Y was de-
fined as: (Serum Creatinine × Urine Y) / (Serum Y ×
Urine Creatinine) × 100%. In healthy controls, serum
and urine hepcidin-25 were expressed as the mean of
four samples collected at different times during the day.
In mice urinary concentrations were normalized for cre-
atinine to correct for differences in urine dilution.
Glomerular filtration rate (GFR) was estimated by the
abbreviated Modification of Diet in Renal Disease equa-
tion in adults [18]. In children GFR was estimated using
the revised Schwartz formula [19].
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Statistical analysis was performed using SPSS 16.0
(SPSS Inc, Chicago, IL). Correlations were assessed by
linear regression, using Spearman’s rho. Mann Whitney
test was used for comparison of FE of hepcidin-25 in
healthy controls and patients with renal disease and for
comparison of urinary concentrations in wild type and
megalin-deficient mice. Statistical significance was de-
noted by two sided P values of <0.05.
Results
In 24 healthy controls fractional excretion (FE) of
hepcidin-25 was 1.9 (IQR 1.0-3.2)% (Table 1). We evalu-
ated 30 patients with glomerular or tubular diseases and
various degrees of impairment in tubular reabsorption.
Median serum creatinine was 107 (IQR 83–147) μmol/l
and proteinuria 4.5 (IQR 1.7-9.4) g/d (Table 1). Renal
disease consisted of idiopathic membranous nephropa-
thy (n = 13), focal segmental glomerulosclerosis (n = 3),
infantile nephropathic cystinosis (n = 7), or other causes
(n = 7). There was an increased FE of hepcidin-25 in pa-
tients with renal disease compared to controls (8.0 ver-
sus 1.9%, p < 0.001). We found a strong correlation
between FE of hepcidin-25 and FE of β2m, Spearman’s
rho = 0.93, p < 0.01, Figure 1). Since β2m is a marker of
proximal tubular reabsorption, this data strongly suggest
that hepcidin excretion is at least partially governed by
this process.
Megalin is a multiligand endocytic receptor localized
in the proximal renal tubules and plays an important
role in the tubular reabsorption of various filtered pro-
teins, amongst which β2m. To prove that the bioactive
mouse hepcidin-1 is reabsorbed in the proximal tubules
in a megalin-dependent manner, we measured urine
hepcidin in wild type and kidney specific megalin-
deficient C57Bl/6 mice. As expected, megalin deficient
mice did excrete low molecular weight proteins
(Additional file 1 Urinary protein profile of wild-type
and megalin deficient mice, web appendix). Urine
hepcidin-1 was 7-fold increased in megalin-deficient mice
Table 1 Clinical and demographic characteristics
Variable Controls (n = 24) Renal disease (n = 30) CABG 1–2 hours (n = 8) CABG 12–24 hours (n = 13)
Male (%) 46 80 88 85
Age (years) 39 ± 12 43 ± 24 65 ± 8 66 ± 10
Serum albumin (g/l) n.a. 34 (24–35) n.a. n.a.
Serum creatinine (μmol/l) 75 (68–83) 107 (23–147) 93 (74–116) 85 (51–102)
eGFR (ml/min/1.73 m2) 84 (77–108) 57 (34–65) 73 (58–95) 85 (17–128)
Proteinuria (g/d) n.a. 4.5 (1.7-9.4) n.a. n.a.
Serum β2m (mg/l) n.a. 2.9 (2.2-4.6) 2.1 (1.6-2.9) 1.8 (1.3-2.5)
Serum hepcidin-25 (nmol/l) 4.4 (3.2-5.8) 3.1 (1.1-5.7) 4.7 (1.5-7.1) 14.1 (11.1-17.8)
Urine β2m (nmol/mmol creatinine) n.a. 142 (13–863) 312 (1528–5239) 66 (21–86)
Urine hepcidin-25 (nmol/mmol creatinine) 0.9 (0.4-1.7) 1.4 (0.3-7.1) 10.4 (0.8-18.7) 52.2 (34.0-112.1)
FE of β2m (%) n.a. 5.1 (0.7-39.1) 14.1 (7.1-20.7) 2.7 (0.8-3.7)
FE of hepcidin-25 (%) 1.9 (1.0-3.2) 8.0 (1.9-20.3) 21.1 (7.2-23.1) 33.1 (22.2-52.9)
Duration of CPB (min) - - 101 (63–147)# 106 (92–125)#
Median (interquartile range), mean ± SD, eGFR = estimated glomerular filtration rate, n.a. = not available, FE = fractional excretion, CABG = coronary artery bypass
grafting, CPB = cardiopulmonary bypass, # one patient underwent off-pump CABG.
Figure 1 Correlation between fractional excretion (FE) of
hepcidin-25 and β2-microglobulin (β2m) in patients with renal
disease without a tubulointerstitial infiltrate (n = 30, triangles),
and in patients at 1–2 hours (n = 8, white circles) and
12–24 hours (n = 13, black circles) after cardiopulmonary
bypass grafting (CABG). FE of hepcidin correlates with FE of β2m,
indicating tubular uptake of hepcidin. However, FE of hepcidin
increased relatively more in patients 12–24 hours after CABG,
suggesting local production in the kidney.
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(n = 5) compared to wild type mice (n = 5, Figure 2;
p < 0.01). Of note, glomerular filtration was not affected in
megalin-deficient mice compared to wild type mice (cre-
atinine clearance 205 ± 146 versus 249 ± 24 μl/min, NS).
We next evaluated urine hepcidin-25 in patients who
underwent cardiopulmonary bypass surgery (Table 1). 24
patients were initially enrolled, but 5 patients were ex-
cluded because of a urinary pH <6 at both time inter-
vals, thus precluding reliable measurement of β2m. All
remaining 19 patients were operated on pump, except
for one patient who had pre-existing impairment of
renal function. Two patients developed acute kidney
injury after cardiac surgery, with AKI defined as a
baseline-to-peak decrease in eGFR by 50% or more dur-
ing the first five days post-operatively. pH was >6 in ap-
proximately 50% of measurements performed in these
19 patients , allowing serum and urine β2m and hepcidin
quantification in eight patients, 1–2 hours after surgery,
and in 13 patients 12–24 hours after surgery. In only 2
patients measurements of β2m and hepcidin could be
performed at both time intervals.
Immediately after surgery, FE of hepcidin-25 and β2m
were 21 and 14%, respectively, and correlated strongly
(Spearman’s rho = 0.79, p = 0.02). The ratio between both
parameters was similar to that in patients with renal dis-
ease, and thus compatible with impairment of tubular
reabsorption. At 12–24 hours after surgery FE β2m de-
creased (3%), indicating recovery from tubular injury.
However, FE of hepcidin-25 increased further (33%). As
a result, FE of hepcidin-25 did no longer correlate with
FE of β2m (Spearman’s rho = 0.18, p = 0.55, Figure 1).
When plotting serum hepcidin versus urinary excretion
of hepcidin (or GFR*serum hepcidin vs urinary excretion
of hepcidin) there was no evidence of a tubular thresh-
old (Figure 3).
Discussion
Our results indicate that hepcidin-25 is reabsorbed by
the renal proximal tubules via megalin-mediated endo-
cytosis. In addition, our data suggest that the increase of
urine hepicidin-25 after cardiac surgery reflects local
production of hepcidin in the kidney.
Urine hepcidin has recently gained interest as a renal
biomarker. However, not much is known about the renal
handling of hepcidin. Because of its small size (2.8 kDa),
free, unbound hepcidin is likely to be filtered by the
glomeruli. After filtration, hepcidin is almost com-
pletely reabsorbed by the renal tubules. This conclu-
sion is based on data from a small number (n = 9)
of healthy controls and patients with thalassemia
and hemochromatosis, where FE of hepcidin was es-
timated to be less than 3% [20,21].
In the present study, FE of hepcidin-25 in healthy con-
trols was approximately 2%, thus confirming earlier re-
ports and compatible with the suggested extensive
tubular uptake [20,21]. In patients with kidney diseases,
FE of hepcidin-25 was increased and correlated strongly
with FE of β2m (r = 0.93, p < 0.01), a low molecular
weight protein that is normally freely filtered by the
glomerulus and almost completely reabsorbed in the
proximal tubule through the megalin receptor. By using
Figure 2 Hepcidin-1 in urine of C57Bl/6 Wild type mice (n = 5)
and mice with kidney-specific megalin deficiency (n = 5). Urine
was normalized for creatinine levels. Data are depicted as lower
quartile, median and upper quartile (boxes), and minimum and
maximum ranges (whiskers). **,P < 0.01;megalin deficient vs. wild
type mice (by Mann Whitney test).
Figure 3 Serum hepcidin-25 versus estimated urinary excretion
of hepcidin-25 in patients 1–2 and 12–24 hours post surgery.
There is no correlation indicating a threshold of serum hepcidin-25
above which urinary excretion steeply increases. Spearman’s rho is
0.91 for 8 patients at day 1 and 0.16 for patients at day 2.
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a mouse model, we confirmed the existence of megalin-
dependent tubular reabsorption of hepcidin-25. Unlike
humans, mice contain two related hepcidin genes,
hepcidin-1 and 2, of which hepcidin-1 is almost exclu-
sively produced in the liver. This peptide is important
for iron homeostasis, and is considered the mouse
equivalent of human hepcidin-25 [3,22,23]. Urine
hepcidin-1 was significantly higher in megalin-deficient
mice (p < 0.01, Figure 2).
We observed that shortly after cardiac surgery, FE of
both hepcidin-25 and β2m were increased and correlated
strongly, reflecting decreased tubular reabsorption.
However, within 24 hours after surgery we observed a
further increase of FE of hepcidin-25, whereas at this
time point tubular injury became less severe as shown
by the reduction in FE of β2m. These findings can be
explained in two ways; either by the occurrence of satur-
ation of tubular reabsorption due to increased tubular
delivery of hepcidin-25 thus exceeding reabsorption
capacity or by production of hepcidin-25 locally in the
kidney. Since we did not observe a threshold (Figure 3),
local production is the most likely explanation.
Data on tubular reabsorption or local production are
scarce. Kulaksiz et al. observed strong hepcidin expres-
sion in the thick ascending limb of the cortex and in the
connecting tubules, but not in the proximal tubules [24].
At the cellular level, hepcidin was localized to the apical
cell pole of the renal epithelial cells, which is suggestive
of luminally directed release of hepcidin in the urine.
Hepcidin-25 may thus be produced by the distal kidney
tubules [24] due to unknown stimuli or by inflammatory
cells such as monocytes [14].
The origin and regulation of locally produced hepcidin-
25 in patients after cardiac surgery merits further studies
in view of the recent evidence that urine hepcidin may
protect against the development of AKI. In a nested co-
hort study Ho et al. compared urine of 22 cardiac surgery
patients with AKI (defined as ≥50% rise in serum creatin-
ine during the first four postoperative days) with urine
from 22 randomly selected cardiac surgery patients with-
out AKI [10]. They observed that hepcidin-25 was in-
creased on the first post-operative day in patients not
developing AKI. The observations of Ho et al. were cor-
roborated by an independent observational study measur-
ing hepcidin through ELISA in 100 cardiac surgery
patients [12]: urine hepcidin was 3–7 times higher 6 and
24 hours after surgery in AKI-free patients (n = 91) com-
pared to 9 patients who developed AKI (defined as ≥50%
rise in serum creatinine or urine output <0.3 ml/kg/hr
during the first seven postoperative days). Additionally, FE
of hepcidin increased from 8 to 40% at 24 h post surgery
in 93 patients exposed to cardiac surgery, and was higher
in patients who did not develop AKI (AKI (n = 25) 27% vs
AKI-free (n = 68) 37%, p = 0.049) [25].
As suggested by others [26], local production of
hepcidin may serve to prevent oxidative damage induced
by free iron and thereby protect against AKI. Some stud-
ies have reported that hepcidin binds divalent metals,
amongst which Fe2+ [27,28].
This study is the first to document local production of
hepcidin in patients after CABG. It has several limitations.
First, we included a limited number of patients. Secondly,
due to a pH <6.0 β2m could not reliably be measured in
all samples. Although alfa-1 microglobulin is a more stable
marker of proximal tubular reabsorption and can reliably
be measured in acidic urine, it is protein-bound and there-
fore it is impossible to calculate the fractional excretion.
Third, this study is a pilot study, and our findings were
not corroborated by histopathological data showing exten-
sive proximal tubular uptake in apical endocytic vesicles,
nor by data on hepcidin expression or mRNA content in
the kidney or macrophages. More extensive studies are
necessary to evaluate the exact timing and location of
hepcidin production, and to identify possible factors influ-
encing this process. Since increased urinary levels of
hepcidin are associated with a decreased risk for post-
surgical AKI, increasing local production may serve as a
strategy to reduce the development of AKI.
Conclusion
In conclusion, our mouse study indicates that proximal
tubular reabsorption of urine hepcidin-1 occurs in a
megalin-dependent manner. In CKD patients FE of
hepcidin-25 correlated strongly with FE of β2m, suggesting
that also in human urinary excretion of hepcidin-25 is
governed by tubular reabsorption of hepcidin. Uncoupling
of FE of hepcidin-25 and β2m in cardiac surgery patients
indicates local production of hepcidin-25. This local pro-
duction of hepcidin-25 may be important in attenuating
post-surgical AKI and merits further investigation.
Additional file
Additional file 1: Urinary protein profile of wild-type and megalin
deficient mice.
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Short summary
We demonstrate that urinary excretion of hepcidin is dependent on tubular
reabsorption. However, we provide evidence that increased levels of urine
hepcidin after cardiac surgery are explained by local production. Local
hepcidin production may be important in attenuating post-surgical acute
kidney injury.
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